<DOC>
	<DOCNO>NCT01580371</DOCNO>
	<brief_summary>This study determine maximum tolerate dose ( MTD ) , dose limit toxicity ( DLT ) , safety pharmacokinetics ( PK ) profile single agent CKD-581 injection patient Lymphoma fail standard therapy . The usefulness regimen evaluate response rate , progression free survival .</brief_summary>
	<brief_title>Safety Pharmacokinetic Profile CKD-581</brief_title>
	<detailed_description>Recently , role transcriptional repression epigenetic modulation carcinogenesis clinically validate several inhibitor histone deacetylases DNA methyltransferases . It long recognize epigenetic alteration tumor suppressor gene one contribute factor carcinogenesis . Inhibitors histone deacetylase ( HDAC ) de-repress gene subsequently result growth inhibition , differentiation apoptosis cancer cell . CKD-581 develop HDAC inhibitor . Such determine maximum tolerate dose ( MTD ) , dose limit toxicity ( DLT ) , safety pharmacokinetics ( PK ) profile single agent CKD-581 injection patient Lymphoma fail standard therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>20 year old Histologically cytologically confirm Lymphoma Multiple myeloma fail standard therapy life prolong treatment exists ECOG ( Eastern cooperative oncology ) performance status ≤ 2 Life expectancy 12 week Hematopoietic : ANC ( Absolute Neutrophil Count ) ≥ 1,500/mm3 , Platelet count ( PLT ) ≥ 100,000/mm3 , Hemoglobin ≥ 9.0g/dL Hepatic : Total bilirubin &gt; 1.5×upper limit normal ( except Gilbert 's syndrome patient ) , aspartate aminotransferase ( AST ) &gt; 3×upper limit normal , alanine aminotransferase ( ALT ) &gt; 3×upper limit normal ( AST , ALT ≤ 5.0×ULN case liver metastasis ) Renal : serum creatinine ≤ 1.5×upper limit normal Serum calcium ≤ upper limit normal ( If Multiple myeloma ) Signed write informed consent Have symptom Brain metastasis History Ischemic heart disease ( e.g. , myocardial infarction , unstable angina pectoris ) Clinically significant heart disease NYHA Class III IV Congestive atrial arrhythmia , within 6 month prior first dose study drug Acute infection blooding tendency would preclude study compliance Other psychiatric disorder condition would preclude study compliance Receiving antitumor therapy ( surgery , immunotherapy chemotherapy ) within 4 week prior first dose study drug ( 6 week nitrosoureas mitomycin C , 2 week radiation therapy ) Other concurrent antitumor therapy Have Cardiac disease nature Administration history Histone Deacetylase Inhibitor History Serious hypersensitivity allergy Pregnant nursing , active serum pregnancy test . Fertile patient must use effective contraception Participation clinical trial within 4 week first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>